Curevac Nv Stock Performance
| CVAC Stock | USD 5.43 0.00 0.00% |
CureVac NV holds a performance score of 15 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.62, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning CureVac NV are expected to decrease at a much lower rate. During the bear market, CureVac NV is likely to outperform the market. Use CureVac NV total risk alpha, value at risk, expected short fall, as well as the relationship between the treynor ratio and downside variance , to analyze future returns on CureVac NV.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in CureVac NV are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, CureVac NV exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Insights Ahead CureVacs Quarterly Earnings - Benzinga | 04/09/2025 |
2 | DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Trims Holdings in CureVac | 05/12/2025 |
3 | Kamada Q1 Earnings Match Estimates | 05/14/2025 |
4 | CureVac BV reports Q1 results | 05/20/2025 |
5 | CureVac to Release Quarterly Earnings on Thursday | 05/21/2025 |
6 | CureVac Maintains Market Outperform Rating with Stable Price Target CVAC Stock News | 05/28/2025 |
7 | CVAC Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders - Business Wire | 06/12/2025 |
8 | CureVac Soars 41 percent in a Month on a 1.25B Buyout Offer From BioNTech - Nasdaq | 06/20/2025 |
9 | CureVac Announces Key Resolutions from Annual Shareholders Meeting - TipRanks | 06/26/2025 |
| Begin Period Cash Flow | 402.5 M |
CureVac NV Relative Risk vs. Return Landscape
If you would invest 298.00 in CureVac NV on April 9, 2025 and sell it today you would earn a total of 247.00 from holding CureVac NV or generate 82.89% return on investment over 90 days. CureVac NV is currently generating 1.1737% in daily expected returns and assumes 6.1393% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than CureVac, and 77% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CureVac NV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CureVac NV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CureVac NV, and traders can use it to determine the average amount a CureVac NV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1912
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CVAC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.14 actual daily | 55 55% of assets are less volatile |
Expected Return
| 1.17 actual daily | 23 77% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 15 85% of assets perform better |
Based on monthly moving average CureVac NV is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CureVac NV by adding it to a well-diversified portfolio.
CureVac NV Fundamentals Growth
CureVac Stock prices reflect investors' perceptions of the future prospects and financial health of CureVac NV, and CureVac NV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CureVac Stock performance.
| Return On Equity | 0.33 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.34 % | ||||
| Operating Margin | (61.28) % | ||||
| Current Valuation | 741.45 M | ||||
| Shares Outstanding | 225.16 M | ||||
| Price To Book | 1.60 X | ||||
| Price To Sales | 2.34 X | ||||
| Revenue | 535.18 M | ||||
| Gross Profit | 458.88 M | ||||
| EBITDA | 209.69 M | ||||
| Net Income | 190.88 M | ||||
| Cash And Equivalents | 540.87 M | ||||
| Cash Per Share | 2.85 X | ||||
| Total Debt | 38.97 M | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | 2.87 X | ||||
| Cash Flow From Operations | 101.85 M | ||||
| Earnings Per Share | 0.94 X | ||||
| Total Asset | 802.83 M | ||||
| Retained Earnings | (1.4 B) | ||||
About CureVac NV Performance
By analyzing CureVac NV's fundamental ratios, stakeholders can gain valuable insights into CureVac NV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CureVac NV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CureVac NV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. Curevac NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 764 people.Things to note about CureVac NV performance evaluation
Checking the ongoing alerts about CureVac NV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CureVac NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CureVac NV is way too risky over 90 days horizon | |
| CureVac NV appears to be risky and price may revert if volatility continues | |
| CureVac NV is unlikely to experience financial distress in the next 2 years | |
| CureVac NV has a poor financial position based on the latest SEC disclosures | |
| About 57.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: CureVac Announces Key Resolutions from Annual Shareholders Meeting - TipRanks |
- Analyzing CureVac NV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CureVac NV's stock is overvalued or undervalued compared to its peers.
- Examining CureVac NV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CureVac NV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CureVac NV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CureVac NV's stock. These opinions can provide insight into CureVac NV's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |